(R)-(-)-α-Methylhistamine dihydrobromide

Pricing Availability Delivery Time Qty
Cat.No. 0569 - (R)-(-)-alpha-Methylhistamine dihydrobromide | C6H11N3.2HBr | CAS No. 868698-49-1
Description: Potent, standard H3 agonist
Chemical Name: (R)-(-)-α-Methyl-1H-imidazole-4-ethanamine dihydrobromide
Purity: ≥99% (HPLC)
Datasheet
Citations (4)
Literature

Biological Activity

Very potent, high affinity H3 agonist (KD = 50.3 nM) that displays > 200-fold selectivity over H4 receptors. Inhibits H3-mediated histamine synthesis and release in the CNS and stimulates H4-mediated eosinophil shape change (EC50 = 66 nM). Part of the Histamine H3 Receptor Tocriset™. (S)-(+)-α-Methylhistamine dihydrobromide (Cat. No. 0572) also available.

Technical Data

M. Wt 287
Formula C6H11N3.2HBr
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 868698-49-1
PubChem ID 45037031
InChI Key RWHNAAABSGVRDT-ZJIMSODOSA-N
Smiles N[C@H](C)CC1=CNC=N1.Br.Br

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 28.7 100

Preparing Stock Solutions

The following data is based on the product molecular weight 287. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.48 mL 17.42 mL 34.84 mL
5 mM 0.7 mL 3.48 mL 6.97 mL
10 mM 0.35 mL 1.74 mL 3.48 mL
50 mM 0.07 mL 0.35 mL 0.7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the products' biological activity.

Buckland et al (2003) Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br.J.Pharmacol. 140 1117 PMID: 14530216

Hew et al (1990) Characterization of histamine-H3 receptors in guinea pig ileum with H3-selective ligands. Br.J.Pharmacol. 101 621 PMID: 1963802

Oishi et al (1989) Effects of histamine H3-agonist (R)-α-methylhistamine and the antagonist thioperamide on histamine modulation in the mouse and rat brain. J.Neurochem. 52 1388 PMID: 2540269

Schwartz et al (1990) A third histamine receptor subtype - characterization, localization and functions of the H3-receptor. Agents Actions 30 13 PMID: 1695431

Shahid et al (2009) Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review. Open Immunol.J. 2 9 PMID:


If you know of a relevant reference for (R)-(-)-α-Methylhistamine dihydrobromide, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Histamine H3 Receptor Agonists

Keywords: (R)-(-)-alpha-Methylhistamine dihydrobromide, supplier, Potent, H3, agonists, Receptors, Histamine, histaminergic, (R)-(-)-alpha-Methylhistamine, dihydrobromide, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience

4 Citations for (R)-(-)-α-Methylhistamine dihydrobromide

Citations are publications that use Tocris products. Selected citations for (R)-(-)-α-Methylhistamine dihydrobromide include:

Spaethling et al (2014) Serotonergic neuron regulation informed by in vivo single-cell transcriptomics. J Clin Invest 28 771 PMID: 24192459

Kim et al (2013) Effects of histamine on cultured interstitial cells of cajal in murine small intestine. Korean J Physiol Pharmacol 17 149 PMID: 23626477

Rapanelli et al (2016) The Histamine H3 Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons. J Biol Chem. 291 21042 PMID: 27510032

Holden et al (2007) Potentiation of NF-κB-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells. FASEB J 152 891 PMID: 17891168


Do you know of a great paper that uses (R)-(-)-α-Methylhistamine dihydrobromide from Tocris? If so please let us know.

(R)-(-)-alpha-Methylhistamine dihydrobromide Reviews

Average Rating:

(Based on 0 Reviews)


1 Star
0%
2 Star
0%
3 Star
0%
4 Star
0%
5 Star
0%

Have you used (R)-(-)-alpha-Methylhistamine dihydrobromide?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.


Literature in this Area

GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Histamine Receptors

Histamine Receptors Scientific Review

Written by Iwan de Esch and Rob Leurs, this review provides a synopsis of the different histamine receptor subtypes and the ligands that act upon them; compounds available from Tocris are listed.

Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.